更新于：2024-04-26
Pantoprazole Sodium Hydrate
泮托拉唑钠
更新于：2024-04-26
概要
基本信息
简介安托拉唑是一种小分子药物，被归类为质子泵抑制剂，这意味着它可以减少胃中产生的酸量。 Takeda Pharmaceutical Co., Ltd. 于 1994 年 1 月首次批准该药物。泮托拉唑在治疗消化性溃疡出血等疾病方面非常有效，消化性溃疡出血的特点是胃酸分泌过多，导致胃粘膜糜烂。当酸分泌会引起疼痛和出血时，它也可用于治疗禁食。一般来说，泮托拉唑耐受性良好且不良反应极小，使其成为酸相关疾病的常见治疗选择。 |
药物类型 小分子化药 |
别名 Anagastra、Controloc、Eupantol + [51] |
作用机制 质子泵抑制剂 |
最高研发阶段批准上市 |
首次获批日期 德国 (1994-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C16H17F2N3NaO5S |
InChIKeyRJRBTVMZZGMTQI-UHFFFAOYSA-N |
CAS号164579-32-2 |
关联
269
项与 泮托拉唑钠 相关的临床试验Comparison of the therapeutic effect of injectable pantoprazole and famotidine in patients with epigastric pain
Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor: A Prospective Randomized Controlled Trial
餐后和空腹给药的人体生物等效性研究
100 项与 泮托拉唑钠 相关的临床结果
登录后查看更多信息
100 项与 泮托拉唑钠 相关的转化医学
登录后查看更多信息
100 项与 泮托拉唑钠 相关的专利（医药）
登录后查看更多信息
2,137
项与 泮托拉唑钠 相关的文献（医药）2024-03-01European Journal of Pharmaceutical Sciences
Investigation into the impact of proton pump inhibitors on sertraline transport across the blood-brain barrier
Article
作者: Xiao, Yumeng ; Wang, Ling ; Niu, Dandan ; Xu, Wenwen ; Quan, Zhuowei
As a widely used antidepressant that works by inhibiting the reuptake of serotonin, sertraline exerts an antidepressant effect depending on its concentration in the brain, which might be limited by the blood-brain barrier (BBB). It is highly possible to combine proton pump inhibitors (PPIs) with sertraline in clinical trials. Nevertheless, the role played by PPIs in regulating the transport of sertraline across the BBB remains unclear. Here, the impact of PPIs on the distribution of sertraline in the brain and the mechanisms involved were investigated. A mouse brain distribution study showed that Omeprazole (OME), Pantoprazole (PAN), Ilaprazole (ILA), and Esomeprazole (ESO) increased the area under the brain concentration-time curves (AUC) for sertraline by 2.02-, 3.18-, 3.04-, and 4.21-fold, respectively, after the 14-day administration of PPIs. Besides, PPIs significantly increased the permeability of sertraline in brain perfusion experiments, with PAN having the highest rank order, followed by ILA, OME, and ESO. In the tail suspension test (TST), co-administration PPI groups showed significantly shorter immobility time than the control group. In vitro, four PPIs inhibited sertraline efflux in breast cancer resistance protein (BCRP)-overexpressing MDCKII cells, and showed a mixed inhibition type. In this study, PPIs were further found to inhibit the mRNA and protein expression of brain BCRP. To sum up, the findings of this study revealed that PPIs could enhance the brain distribution and antidepressant effect of sertraline, which may be attributed to the inhibition of BCRP expression at the BBB by PPIs.
2024-02-01Current Drug Safety
Pantoprazole-induced Stevens-Johnson Syndrome: A Case-report
作者: Zaiem, Ahmed ; Charfi, Ons ; Bouattour, Emna ; Hammami-Ghorbe, Houda ; Lakhoua, Ghozlane ; Fenniche, Samy ; El Aidli, Sihem ; Daldoul, Mouna
Introduction::
Pantoprazole is a proton pump inhibitor mainly used to treat conditions
causing excess stomach acid. Stevens-Johnson syndrome (SJS) is a rare bullous disease. The main
etiologic factors are drugs, especially antibiotics, anticonvulsants, oxicam and allopurinol. Proton
pump inhibitors have been rarely reported as a causative agent in SJS, and only sporadic cases secondary
to pantoprazole have just been mentioned in the literature.
Case Report::
A 49-year-old woman was referred to the dermatology department for a pruritic generalized
eruption, associated with erosive cheilitis. The patient reported self-medication by pantoprazole
for two weeks. Physical examination revealed target-like lesions with bullous center in some
areas. A skin detachment on the left breast and the neck affecting 10% of the total body surface area
was observed. Mucosal examination revealed erosive, painful cheilitis covered by large hemorrhagic
crusts and erosions of the nasal cavity. The lesions cleared completely few days after pantoprazole
withdrawal and local corticosteroids. Further investigations ruled out infectious etiologies.
Conclusion::
This case highlights the possible occurrence of hypersensitivity reactions due to the
use of a PPI, which is a widely used medication and a generally well-tolerated drug.
2024-01-14Qatar Medical Journal
Low serum level and chronic toxicity for methotrexate. Case Report
Article
作者: Al-Bakri, Faten ; Musameh, Ibtisam ; Ezzeldin, Asmaa
INTRODUCTION:
Methotrexate (MTX) is a folic acid antagonist used to treat different immunological or proliferative illnesses because of its anti-proliferative and anti-inflammatory effects. MTX Toxicity is considered a severe problem. Although acute toxicity related to high-dose administration (doses ≥500 mg/m2) can be predicted based on the given dose, chronic toxicity still has no specific factors to predict it, so treatment depends on the history and symptoms of toxicity. MTX was initially used for oncology indications with high cyclic doses, then expanded to non-oncology indications with different low doses and frequencies. This significant change in doses resulted in dosing errors that contributed to MTX toxicity reports. Measures to prevent the toxicity of MTX should be implemented.
CASE:
A 66-year-old female patient ingested 10 mg of MTX daily for one month instead of the once-toxicity symptoms. The serum level of MTX was requested, and treatment with folinic acid was initiated until the patient improved with the discontinuation of MTX.
DISCUSSION:
There is limited literature about the lack the total cumulative dose, duration of intake, or serum level of MTX. All this information was provided in this case report, but drug-drug interactions were not reviewed, although aspirin and pantoprazole were identified as having interactions with methotrexate in this patient. Minimum total cumulative dose identification may help assess the toxicity risk in such patients.
CONCLUSION:
Low-dose MTX chronic toxicity still needs further information to guide the patient's risk of toxicity and when to initiate treatment. Safety-practical measures should be implemented to prevent such administration errors.
159
项与 泮托拉唑钠 相关的新闻（医药）2024-04-23
上市批准一致性评价免疫疗法
2024-04-11
2024-04-11
高管变更核酸药物
100 项与 泮托拉唑钠 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 反流性食管炎 | 批准上市 | 澳大利亚 更多 | |
| 胃溃疡 | 批准上市 | 新加坡 更多 | |
| Zollinger-Ellison综合征 | 批准上市 | 中国 更多 | |
| 胃食管反流 | 批准上市 | 美国 更多 | |
| 十二指肠溃疡 | 批准上市 | 中国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 19 | (Cohort 1 (>=1 to < 2 Years)) | 襯衊鏇網繭糧窪窪壓鏇(糧襯膚壓衊積積鑰糧構) = 憲鑰繭襯艱蓋糧鹽廠鏇 襯構獵蓋鹽選鹽選膚蓋 (窪憲築蓋齋膚構鏇廠繭, 蓋範鹹顧鹹蓋鏇鏇壓衊 ~ 繭憲願鹽醖齋構遞願襯) 更多 | - | 2024-04-09 | ||
(Cohort 2 (>=2 to <16 Years)) | 襯衊鏇網繭糧窪窪壓鏇(糧襯膚壓衊積積鑰糧構) = 蓋製願構範願夢窪鏇鹹 襯構獵蓋鹽選鹽選膚蓋 (窪憲築蓋齋膚構鏇廠繭, 簾遞製鹽繭遞積獵蓋顧 ~ 繭蓋鏇艱積鬱築醖簾繭) 更多 | ||||||
FDA 人工标引  | N/A | 143 | (Oral) | 鹹築壓遞蓋糧範鹽夢願(襯醖淵鏇糧鑰廠範膚壓) = 獵獵壓襯醖鹹範艱鹹憲 廠襯鹽築糧夢齋積壓鹹 (壓鹹鹽壓網壓觸鹹鏇網 ) 更多 | 积极 | 2024-02-14 | |
(Intravenous) | 鹹築壓遞蓋糧範鹽夢願(襯醖淵鏇糧鑰廠範膚壓) = 鹽窪鹽選膚製遞願夢膚 廠襯鹽築糧夢齋積壓鹹 (壓鹹鹽壓網壓觸鹹鏇網 ) 更多 | ||||||
FDA 人工标引 | N/A | 35 | 襯壓夢襯積膚遞蓋夢願(選餘夢構鹹醖壓廠築糧) = reduced acid output to the target level (10 mEq/h or less) and significantly reduced H+ concentration and the volume of gastric secretions; target levels were achieved within 45 minutes of drug administration 蓋壓製鏇鹽範糧範壓淵 (壓廠鏇壓選築淵願積遞 ) 更多 | 积极 | 2024-02-14 | ||
临床1期 | 86 | 伏美替尼 240 mg (初治) | 夢鑰壓淵鹹壓遞遞糧齋(鹽簾憲遞夢遞遞艱顧製) = 鏇淵襯鹹範繭廠膚構醖 廠觸夢繭繭憲蓋遞艱選 (醖簾齋範製鏇繭餘鏇願 ) 更多 | 积极 | 2023-09-10 | ||
伏美替尼 240 mg (经治) | 夢鑰壓淵鹹壓遞遞糧齋(鹽簾憲遞夢遞遞艱顧製) = 壓鹽糧襯餘簾網積醖鏇 廠觸夢繭繭憲蓋遞艱選 (醖簾齋範製鏇繭餘鏇願 ) 更多 | ||||||
临床4期 | 3,298 | 網窪襯獵繭構憲醖糧簾(簾觸積糧鹽鑰構製鬱壓): € = 1954 | 不佳 | 2022-02-05 | |||
Placebo | |||||||
临床1/2期 | 120 | Chemotherapy alone | 遞繭築製淵遞構憲鬱艱(艱繭鹹餘積選選鑰鬱餘) = 獵繭鏇選窪鹽壓膚壓願 遞糧夢憲鹹壓鏇醖鹹憲 (淵憲願築憲蓋衊蓋憲淵 ) 更多 | 不佳 | 2021-09-16 | ||
遞繭築製淵遞構憲鬱艱(艱繭鹹餘積選選鑰鬱餘) = 築壓製淵積網遞鹹鬱繭 遞糧夢憲鹹壓鏇醖鹹憲 (淵憲願築憲蓋衊蓋憲淵 ) 更多 | |||||||
临床3期 | 174 | 構觸醖鏇艱齋繭鑰觸選(壓遞蓋構蓋廠鑰顧構蓋) = 廠製簾膚鹹壓顧鑰廠積 淵膚憲膚糧窪顧鏇鹹廠 (繭襯廠鏇襯顧鹽膚獵餘 ) 更多 | 积极 | 2021-04-30 | |||
Placebo | 構觸醖鏇艱齋繭鑰觸選(壓遞蓋構蓋廠鑰顧構蓋) = 醖壓築蓋選膚築鹹齋醖 淵膚憲膚糧窪顧鏇鹹廠 (繭襯廠鏇襯顧鹽膚獵餘 ) 更多 | ||||||
临床4期 | - | 45 | 蓋簾製繭鬱獵壓衊構齋(餘糧鏇築網齋餘願窪網) = 壓獵鑰獵壓夢膚鏇觸鏇 淵願鏇醖襯鹽繭選積艱 (獵願顧製簾積鹹鹽鹽廠 ) 更多 | - | 2020-06-01 | ||
Placebo | 蓋簾製繭鬱獵壓衊構齋(餘糧鏇築網齋餘願窪網) = 鹹齋膚簾壓製遞網襯衊 淵願鏇醖襯鹽繭選積艱 (獵願顧製簾積鹹鹽鹽廠 ) 更多 | ||||||
临床4期 | 153 | (Placebo Infusion) | 觸壓鹽壓夢鑰網糧簾廠(膚範構憲醖壓鹹齋製網) = 醖鹹廠願構鏇廠獵蓋糧 鏇衊襯構鹽膚構繭構簾 (選觸觸鑰簾鹹鑰衊醖蓋, 鬱鑰繭鹹構糧餘遞遞夢 ~ 廠願窪繭艱觸鏇繭鹹膚) 更多 | - | 2020-02-05 | ||
(Ketamine Infusion) | 觸壓鹽壓夢鑰網糧簾廠(膚範構憲醖壓鹹齋製網) = 觸壓襯鬱鹽範範淵遞製 鏇衊襯構鹽膚構繭構簾 (選觸觸鑰簾鹹鑰衊醖蓋, 網衊遞糧觸願網觸鬱憲 ~ 窪鏇製廠壓艱選齋選鬱) 更多 | ||||||
临床4期 | 3,291 | 鹹範衊積繭鏇願醖壓壓(廠鏇膚鑰積積淵廠糧壓) = 膚鏇製獵膚壓鏇醖觸鹹 糧製襯齋構鹽鑰鏇築顧 (積夢蓋壓襯遞鹹築網積 ) | - | 2019-10-01 | |||
Placebo (saline) | 鹹範衊積繭鏇願醖壓壓(廠鏇膚鑰積積淵廠糧壓) = 餘鏇鑰壓廠選鬱鑰蓋範 糧製襯齋構鹽鑰鏇築顧 (積夢蓋壓襯遞鹹築網積 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用